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Efficacy of HFA-beclomethasone dipropionate
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fluticasone propionate (1000 mg day71) in
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Hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) extra-fine aerosol and HFA-fluticasone
propionate (HFA-FP) are chlorofluorocarbon-free inhalers.
We conducted an 8-week, open study to demonstrate the equivalence of HFA-BDP (800 mg day71) and HFA-FP
(1000 mg day71) in moderate to severe asthma. Symptomatic patients on 500–1000 mg day71 CFC-BDP (or
equivalent) and short-acting b-agonist, were randomized to HFA-BDP (n=101) or HFA-FP (n=97) after 7–14
(+2) day run-in.
In the intent-to-treat (ITT) population (n=198), both treatments provided clinically and statistically significant
improvements in asthma control, with increases in peak expiratory flow in the morning (AM PEF) and asthma
symptoms (within treatment analysis P50?05). Mean (SE) change in AM PEF from baseline at week 8 was
equivalent (defined as 90% CI for the mean difference between treatments within+25 lmin71) in the two groups:
29?59 (5?19) 1min71 for HFA-BDP vs. 17?3 (5?45) 1min71 for HFA-FP (90% CI70?02, 24?91). For the per-
protocol population (n=121), the mean (SE) change in AM PEF from baseline was not equivalent; AM PEF
improved to a significantly greater extent in the HFA-BDP group than HFA-FP group [34?84 (7?08) vs. 20?63 (7?32)
1min71 P50?01; 90% CI; 2?66, 31?10]. At week 8 in the ITT population, there were no statistically significant
differences in FEV1, b-agonist use, asthma symptom/sleep disturbance scores, or percentage of days without
asthma symptoms/sleep disturbance. There was a significantly greater reduction from baseline in mean eosinophil
count for HFA-BDP compared with HFA-FP at weeks 3 and 8 (P50?01), and eosinophil cationic protein value at
week 8 (P50?01). Both treatments were well tolerated and there were no statistically significant differences in
urinary cortisol creatinine parameters.
In conclusion, this study showed that, in patients with moderate-to-severe symptomatic asthma, HFA-BDP
extra-fine aerosol 800mg71 was at least as effective and equally well tolerated as 1000mg day71 HFA-FP.
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The removal of chlorofluorocarbon (CFC) propellants
from pressurized metered-dose inhalers (pMDIs) for the
treatment of asthma has involved the re-formulation of
commonly used corticosteroids with alternative CFC-free
propellants, such as hydrofluoroalkane-134a (HFA). Dif-
ferences in the physical properties of these propellants can
result in the need to adjust the daily corticosteroid dosage;
for example, HFA-beclomethasone dipropionate (HFA-Received 21 June 2000 and accepted in revised form 8 December
2000.
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0954-6111/01/030212+09 $35?00/0BDP) extra-fine aerosol (3M Pharmaceuticals) provides
equivalent control of asthma to CFC-BDP at a dosing ratio
of approximately 1:2?5 (1,2). However, HFA-fluticasone
propionate (HFA-FP) and CFC-FP (Glaxo Wellcome)
have been shown to have equivalent anti-asthmatic ecacy
(3) and are licensed for use at the same dose.
The relative ‘potency’ of HFA- and CFC-based pMDIs
may be attributed to differences in lung deposition — in
turn dependent on the particular characteristics of each
inhaler (e.g. particle size distribution, spray force and
temperature). In gamma camera imaging studies using
99mtechnetium-radiolabelled BDP, 50–60% of the dose
leaving the HFA-BDP extrafine aerosol pMDI was
deposited in the lung, compared with up to 10% of the
CFC-BDP dose (4–6). To date, there have been no
published radiolabelled deposition studies using CFC-FP# 2001 HARCOURT PUBLISHERS LTD
HFA-BDP AND HFA-FP IN ASTHMA 213or HFA-FP in humans. However, in a mechanical lung
model, the deposition of CFC-FP to the lung airways was
similar to CFC-BDP (19% vs. 18% ex-actuator) (7). The
model result of 56% ex-actuator lung deposition for HFA-
BDP agreed well with the result seen in humans.
In this study, we investigated the relative ecacy and
safety of HFA-BDP extra-fine aerosol 800mg day71 and
HFA-FP 1000 mg day71. The dosing ratio of the two agents
was based on the following observations: HFA-FP and
CFC-FP have equivalent ecacy at the same dose (1:1
ratio) (3); CFC-FP has demonstrated equivalent ecacy
and safety to CFC-BDP at approximately half the daily
dose (2:1 ratio) (8–11); CFC-FP 400 mg day71 and HFA-
BDP 400mg day71 were shown to be equivalent with regard
to ecacy and safety (1:1 ratio) (12); and studies support a
recommended daily dosing ratio for HFA-BDP extra-fine
aerosol and CFC-BDP of 1:2?5 (1,2). This study was
performed in a cohort of symptomatic asthma patients
maintained on a mid-dose of inhaled steroids. The increases
in dose chosen were in line with recommendations from the
Global Initiative for Asthma (13) and normal clinical
practice.
Methods
PATIENTS
Eligible study participants were non-smoking adults (aged
18–75 years) with at least a 4-week clinical history of
moderate to severe asthma: a peak expiratory flow (PEF) of
50–80% of predicted normal after withholding b-agonist
for at least 4 h, and PEF reversibility 10% from baseline
within 30min of inhalation of salbutamol 200 mg, or
equivalent. Asthma symptoms had to clinically indicate
the necessity of an increase in steroid dose on previous
treatment 500–1000 mg day71 CFC-BDP (or equivalent)
with ‘as required’ short-acting b-agonist. Individuals also
had to show that they could use both a press-and-breathe
pMDI and a peak flow meter correctly.
Women were not included in the study if they were
pregnant (or likely to become pregnant) or if they were
lactating. Subjects with stable, treated, chronic conditions
other than asthma could be included; individuals were
excluded if they showed any clinically significant unstable
immunological, neoplastic, endocrine, haematological, he-
patic, cardiac, renal, gastrointestinal, neurological, or
psychiatric abnormality, or if they had another significant
respiratory disorder. Individuals were not included if they
had experienced a significant upper or lower respiratory
tract infection in the past 2 weeks; if they had been treated
with intra-articular, intra-muscular, or intra-vascular ster-
oids in the past 8 weeks; or if they had participated in
another clinical drug trial or taken oral steroids, mono-
amine oxidase inhibitors, tricyclic anti-depressants, or beta-
blockers in the past 4 weeks. Subjects were also excluded if
they had known hypersensitivity or idiosyncratic reaction
to sympathomimetic drugs or inhaled steroids, or if they
were using BDP (or equivalent) as a nasal spray at a daily
dose of 4400mg.STUDY DESIGN
This was an open-label, parallel-group, randomized,
comparative study conducted in Germany, France, The
Netherlands, and Belgium at 31 centres. The study was
performed in accordance with Good Clinical Practice and
the ethical principles outlined in revised Declaration of
Helsinki (South Africa, October 1996).
Eligible subjects, having given written informed consent,
participated in a 7–14-(+2) day run-in period, after which
subjects were re-assessed for signs and symptoms of
asthma: PEF measured in the morning (AM PEF)50–
80% of predicted normal with either a sleep disturbance
score1 on at least one night, a mean daily use of 2 puffs
of short-acting b-agonist, or a daily asthma symptom score
of 2 on at least 3 days for one symptom. Patients meeting
these criteria were randomized to receive 8 weeks treatment
with HFA-BDP extra-fine aerosol (800 mg day71; 100 mg
puff71, 4 puffs b.d.) or HFA-FP (1000 mg day71; 125 mg
puffs71, 4 puffs b.d.). Clinical visits took place at baseline
(day 1+2), week 3 (day 21+2), and week 8 (day 56+2).
OUTCOME MEASURES
PEF, asthma symptom scores, sleep disturbance scores and
b-agonist use were recorded daily in a diary and averaged
for the following time points: baseline (last 5 days of run-in
period before day 1), week 3 (5 days following day 21) and
week 8 (5 days before day 56). For PEF, patients were
asked to record the daily average of three AM PEF
measurements, and three PEF measurements taken in the
evening before retiring (PM PEF). The primary ecacy
parameter was the mean change from baseline in AM PEF
at week 8.
Pulmonary function tests [forced expiratory volume in 1
sec (FEV1), forced expiratory flow of 25% of the vital
capacity (FEF25%), FEF25–75%, forced vital capacity
(FVC), inspiratory vital capacity (IVC) and Tiffeneau
indices] were performed with the patient in a sitting or
standing position at all clinic visits. Blood samples were
also drawn at these visits for analysis of eosinophil count
and eosinophil cationic protein (ECP) (Pharmacia CAP
System ECP FEIA).
Adverse events were elicited at each clinic visit. Particular
attention was paid to candidia infection and dysphonia.
Oropharyngeal candida infection was assessed by visual
inspection and the presence of clinical signs and symptoms
(e.g. sore throat or mouth, erythema and plaques).
Individuals were asked to record their assessment of
dysphonia on a visual analogue scale of ‘none’ to ‘no
voice’. Samples were also collected for urine cortisol/
creatinine (UCC) ratio analysis at clinic visits.
COMPLIANCE
To assess compliance, all study inhaler canisters were
weighed on dispatch and return. Predicted and actual
inhaler canister weights were converted to an estimate of
the number of doses administered using mean shot weights.
214 M. AUBIER ET AL.Individuals were considered to be compliant if the total
number of actuations was+40% of predicted during the 8-
week study. During active treatment, non-compliance was
further defined as more than four missing AM PEF
measurements during a 7-day period.
STATISTICAL ANALYSES
The null hypothesis of this study was that the mean change
from baseline in AM PEF at the end of the study for
patients on HFA-BDP 800 mg day71 was unequal by more
than +25 l min71 of that to HFA-FP 1000mg day71. The
rejection of this hypothesis (tested using the two one-sided
tests procedure) would imply equivalence of the two active
treatments [i.e. if a 90% confidence interval (CI) con-
structed for the mean difference between the two treatments
was completely contained within an interval of
+25 lmin71]. Given that recently published trials have
shown the standard deviation of the change in AM PEF
from baseline to be 50 lmin71 during treatment (14,15), 72
patients were required in each treatment group to ensure
80% power with a=0?05.
All analyses were performed on the intent-to-treat (ITT)
study population (all patients who received one dose of
active study medication and had at least one data point
after the run-in period). Supportive analyses of the primary
ecacy parameter were performed on a per-protocol
population (subjects with no major protocol violations).
Between treatment groups, comparisons of qualitative
measures were made using a Mantel–Haenszel test adjusted
by country or a Fischer’s exact test if the expected number
of patients was less than five. Where data were normally
distributed, quantitative measures were analysed using an
analysis of variance (ANOVA), taking into account
treatment effect, country effect, and country-by-treatment
interaction. In cases of non-normality in one or both
treatment groups, the Wilcoxon test was used, taking into
account treatment effect. An assessment found that data
could be pooled across study centres.
Results
PATIENTS
The ITT population comprised 101 patients randomized to
HFA-BDP and 97 randomized to HFA-FP. The groups
were well matched, with a similar percentage of males
(59?4% in the HFA-BDP group and 54?6% in the HFA-FP
group): there were no significant differences between
the groups with regard to demographical characteristics,
pulmonary function parameters, reversibility, percentage
of days/nights without asthma symptoms/sleep
disturbance, short-acting b-agonist use or serum ECP levels
(Table 1). However, patients in the HFA-BDP group had a
significantly greater mean baseline eosinophil count than
patients on HFA-FP (0?24 vs. 0?196109 cells 171;
P=0?03).
With regard to baseline safety parameters, one patient in
the HFA-BDP group had an isolated lesion of candidiasisat baseline. There were no statistically significant differ-
ences between the groups in the degree of dysphonia. The
mean corrected UCC value (excluding all samples with a
creatinine 4?3 mmol 171 at baseline was significantly
greater in the HFA-FP group than the HFA-BDP group
(34?06 vs. 22?58 nmol mmol71; P50?05).
WITHDRAWALS AND COMPLIANCE
Reasons for withdrawal in both groups included pre-
existing violation of entry criteria, loss to follow-up and
withdrawal of consent. Eight (7?8%) patients on HFA-
BDP and six (6?1%) patients on HFA-FP withdrew during
the course of the study. For three patients on HFA-BDP,
the reason for withdrawal was because of an adverse event
(dysphonia and headache, cough, asthma symptoms). In the
HFA-FP group, one patient withdrew because of dyspho-
nia and increased asthma symptoms; another patient
withdrew because of the different feel of the new inhaler.
Compliance during the study was good in both groups:
75?0% of patients on HFA-BDP and 86?5% of patients on
HFA-FP met compliance criteria. The mean percentage of
compliant patients was similar in the HFA-BDP and HFA-
FP groups 84?8% and 84?2% respectively).
EFFICACY
In the ITT population, the mean (SE) change from baseline
in AM PEF at the week 8 visit was 29?59 (5?19) 1min71 for
HFA-BDP and 17?13 (5?45) 1min71 for HFA-FP; a
difference of +12?46 1min71 (90% CI: 70?02, 24?91)
(Fig. 1). The CI fell within the defined equivalence interval
(+25 1min71), demonstrating the equivalence of the two
treatments. AM PEF improved over the course of the study
with both treatments. Significant improvements within
treatment groups were observed at week 8 for HFA-BDP
(P50?01) and HFA-FP (P50?05).
The primary ecacy parameter was also assessed in the
per-protocol population. Seventy-seven (39%) patients
deviated from the protocol to an extent that would
potentially affect the primary ecacy measure and so were
excluded from the per-protocol population. The most
common reasons for exclusion were poor compliance with
study medication (40 patients) and poor compliance with
diary card completion prior to the final clinic visit (20
patients). Baseline AM PEF values in the perprotocol
population (n=121) were 347?0 1min71 in the HFA-BDP
group and 345?9 1min71 in the HFA-FP group. The per-
protocol analysis did not confirm the equivalence of HFA-
BDP 800mg day71 and HFA-FP 1000mg day71; the mean
(SE) change from baseline in AM PEF at week 8 was greater
in the HFA-BDP group (n=58) than the HFA-FP group
(n=63) [34?84 (7?08) vs. 20?63 (7?32) 1min71]. Statistical
analysis of the difference between the mean values (14?21
1min71) showed that the results were not equivalent (90%
CI: 2?66, 31?10) (i.e. the CI was not contained within the
defined equivalence limit of +25 1min71).
The remainder of the ecacy parameters were analysed
using statistical tests to detect significant differences
TABLE 1. Baseline characteristics (n=198)
HFA-BDP
800mg day71
(n=101)
HFA-FP
1000 mg day71
(n=97)
P-value
Age (years) 50?1 51?9 0?49
Range 19?0–76?0 20?0–78?0
Height (cm) 170?3 170?2 0?39
Weight (kg) 75?8 78?2 0?33
AM PEF (SD) (l min71) 352?2 (82?6) 345?2 (73?1) 0?68
Range 208?0–542.0 222?0–506?0
PM PEF (l min71) 364?5 359?9 0?73
Range 218?0–602?0 206?0–578?0
PEF reversibility (%) 16?2 15?7 0?24
AM PEF % predicted 64?8 64?9 0?98
FEV1 (l) 2?27 2?21 0?81
FEV1% predicted 71?7 71?8 0?51
Mean % days/nights without
Wheeze 33?8 35?8 0?94
Cough 39?8 39?8 0?93
Shortness of breath 30?7 28?5 0?52
Chest tightness 45?7 45?2 0?86
Daily asthma symptoms 8?80 9?38 0?75
Sleep disturbance 42?2 40?4 0?72
b-agonist
Use (% days) 85?4 85?4 0?89
Mean daily puffs 3?51 3?74 0?65
Eosinophil count (109 cells l71) 0?24 0?19 0?03
ECP (mg l71) 22?3 21?8 0?16
% PEF reversibility from baseline calculated from the PEF measurement within 30min of inhalation of b-agonist; all values
are means.
FIG. 1. (a) Mean (SE) change from baseline in AM PEF (l min71) by study time period. (ITT population, n=198; HFA-
BDP 800mg day71 (n=101); HFA-FP 800 mg day71 (n=97). (b) per-protocol population, n=121. *Significant change
from baseline (P50?05); {Significant equivalence (90% CI:70?02, 24?91; equivalence limit+ 25 l min71. HFA-BDP
800 mg day71 (n=58); HFA-FP 1000 mg day71 (n=63).
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extent in the HFA-BDP group than the HFA-FP group at
both week 3 (17?4 vs. 5?96 1min71) and week 8 (24?9 vs.
12?0 1min71), however, the difference was not statisticallysignificant at either time point (P=0?13). Spirometry was
also improved in both groups over the course of the study.
There were no statistically significant differences between
the HFA-BDP and HFA-FP treatment groups in the mean
FIG. 2. Mean change from baseline (mean of the last 5 days of run-in period) in percentage of days/nights without asthma
symptoms/sleep disturbance at (a) week 3 (mean of the 5 days after clinical visit in week 3) (n=198); and (b) week 8 (mean of
the 5 days after clinical visit in week 8) (n=198). *P50?05 within treatment group change from baseline; **P50?01 within
treatment group from baseline;{number of days without any day the asthma symptoms (no wheeze, no cough, no shortness
of breath, no chest tightness). HFA-BDP 800 mg day71 (n=101); HFA-FP 1000mg day71 (n=97).
FIG. 3. Mean change from baseline in ECP value (mg l71)
at weeks 3 and 8 (n=198). HFA-BDP 800 mg day71
(n=101); HFA-FP 1000 mg (n=97).
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(0?05) 1; P=0?18] or week 8 [0?11 (0?05) vs. 0?07 (0?05) 1;
P=0?21], Patients treated with HFA-BDP showed a
statistically significant (P50?05) within-treatment group
improvement in FEV1 at both week 3 and week 8, however
HFA-FP-treated patients failed to improve significantly
over baseline values. Similarly, there were no statistically
significant differences between the treatment groups in the
mean change from baseline in FEF25%, FEF25–75%, FVC,
IVC or Tiffeneau parameters at weeks 3 or 8.
Improvements from baseline were seen across the asthma
symptom scores for wheeze, cough, shortness of breath and
chest tightness, and sleep disturbance score for both
treatments at weeks 3 and 8. In addition, there were no
statistically significant differences between the groups in the
mean change from baseline in percentage of days without
wheeze, cough, shortness of breath or chest tightness, or
nights without sleep disturbance at weeks 3 and 8 (Fig. 2).
However, at week 3, the mean (SE) change from baseline in
percentage of patients free from daily asthma symptoms
was significantly greater in the HFA-BDP group compared
with the HFA-FP group [18?32% (3?4%) vs. 6?84% (2?6%);
P=0?03]. This trend was maintained at week 8, although
the difference was no longer significant [24?32% (4?39%) vs.
18?20% (4?0%); P=0?23).
Patients in both groups used short-acting b-agonist
rescue medication less as the study progressed; the mean
(SE) reduction in percentage of days using short-acting b-
agonist was greater for HFA-BDP than HFA-FP:
716?16% (3?45%) vs. 711?34% (3?30%) at the week 3
clinic visit and723?96% (4?29%) vs.718?89% (4?05%) at
week 8. There were no statistically significant differences
between the groups in the proportion of days short-acting
b-agonist was used or the mean daily intake of short-acting
b-agonist medication at weeks 3 or 8.The mean eosinophil count reduced to a significantly
greater extent from baseline in the HFA-BDP group than
the HFA-FP group at week 3 (70?05 vs. 0?006109 cells
l71; P50?01) and week 8 (70?04 vs. 0?006109 cells l71;
P50?01). Although the mean change from baseline in ECP
value was not statistically significantly different between the
groups at week 3, the ECP value decreased to a significantly
greater extent in patients on HFA-BDP than HFA-FP at
week 8 (73?64 vs. 72?33mg l71; P50?01) (Fig. 3).
SAFETY
In the 198 patients of the ITT population, a similar number
in both the HFA-BDP and HFA-FP groups experienced at
least one adverse event [25 (12?63%) vs. 33 (16?67%)].
There were no statistically significant differences between
FIG. 4. 95% confidence intervals on mean change from
baseline in corrected UCC at week 8.
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events, and the majority of events were of mild-to-moderate
severity. Table 2 shows the number of adverse events
considered to be possibly or probably treatment-related,
most of which affected the respiratory system and the
application site.
There were no statistically significant differences between
the groups in change from baseline in corrected (i.e.
samples with the creatinine 4?3mmol 171 omitted)
(Fig. 4) or uncorrected UCC ratio, the percentage change
of corrected UCC from baseline, or the distribution of
corrected UCC ratios according to the normal range at
week 3 or 8.
Discussion
With the phasing-out of CFC propellants from all asthma
pMDIs, it is necessary to switch a vast number of patients
from their current inhaled corticosteroid therapy to a CFC-
free alternative. To maintain compliance, patients currently
using a pMDI should continue using this method of
delivery. The physical characteristics of HFA corticosteroid
pMDIs may, however, not be the same as their CFC-based
counterparts and thus, the daily steroid dose may need to
be altered. For example, a switch from CFC-BDP 1000mg
day71 to HFA-BDP extra-fine aerosol 400 mg day71 seems
reasonable based on the results of several comparative
studies with these agents, including a robust dose-response
study (1,2). For other agents, such as CFC-FP, the ecacy
and safety does not appear to have been altered during
reformulation with HFA propellant (3), HFA-FP isTABLE 2. Number of patients experiencing treatment-related
adverse events (n=198)
Patients (%)
HFA-BDP
(n=101)
HFA-FP
(n=97)
Fungal infection 4?0 3?1
Dysphonia 1?0 3?1
Site sensation 1?0 3?1
Headache 2?0 0
Cough 1?0 1?0
Increased asthma symptoms 1?0 1?0
Unpleasant taste 0 1?0
Pharyngitis 1?0 0
Dizziness 0 1?0
Mouth ulceration 1?0 0
Stomatitis 0 1?0
Weight increase 0 1?0
Pruritus 1?0 0
Includes any adverse events experienced by the 14 with-
drawn patients prior to study withdrawal.licensed on an equivalent (1:1) dosing basis (mg for mg) to
CFC-FP.
Given the dosing ratios described above, the observation
that CFC-FP and CFC-BDP have equivalent ecacy and
safety at approximately half the daily dose (a 1 : 2 ratio) (8–
11), and the results from a recent study that shows HFA-
BDP extra-fine aerosol to produce equivalent control of
asthma and similar tolerability to CFC-FP at the same dose
(400mg day71) (12), the hypothesis on which this study was
based — the equivalence between HFA-BDP extra-fine
aerosol 800 mg day71 and HFA-FP 1000mg day71 —
seemed appropriate. The results demonstrated adequate
control of asthma and good tolerability for both HFA-BDP
extra-fine aerosol 800mg day71 and HFA-FP 1000 mg
day71 in a group of patients with symptomatic asthma
on a mid-dose of inhaled corticosteroids.
Both treatments produced statistically significant im-
provements from baseline in AM PEF at weeks 3 and 8
within treatment groups. Using a predefined parameter of
+25 1min71 to define the limits of equivalence for AM
PEF between the two treatments, the improvements from
baseline in AM PEF was shown to be significantly
equivalent for HFA-BDP 800 mg day71 and HFA-FP
1000mg day71 after 8 weeks’ treatment in the ITT popula-
tion, showing a trend in favour of HFA-BDP. The primary
ecacy parameter, mean change from baseline in AM PEF
at week 8, was also analysed in the per-protocol population
in this study. The per-protocol population excluded all
patients with major protocol violations, and therefore, for
assessment of statistical equivalence, was a more rigorous
analysis. At week 8, the 90% CI, constructed from the
difference between treatments did not fall within +25
1min71 — the defined limits of equivalence. Therefore, the
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found that HFA-BDP 800 mg day71 and HFA-FP 1000 mg
day71 were not statistically significantly equivalent.
Improvements in pulmonary function parameters were
similar for both treatments with no statistically significant
differences detected in patients in the ITT population.
While parameters such as AM PEF and FEV1 are proven
indicators of the effect of inhaled corticosteroid treatment
on respiratory function in asthma, these tests predomi-
nantly assess changes in the large airways of the lung.
However, in asthma inflammation is not only restricted to
the large airways; the small airways, which comprise a
much larger proportion of the surface area, are also
affected. It is dicult to measure changes in respiratory
flow in the small airways of the lung because resistance in
this area is low. Evaluation of changes in asthma
symptoms, and their impact on the everyday lives of
individuals can be useful in this regard.
During this study, asthma symptom and sleep distur-
bance scores improved in both groups. Similarly, the
percentage of days that patients reported to be free from
wheeze, cough, chest tightness and shortness of breath, and
nights free from sleep disturbance improved in both groups.
The improvements tended to be greater for HFA-BDP than
HFA-FP (with the exception of percentage of nights free
from sleep disturbance) and the difference between the
groups in the percentage of days without daily asthma
symptoms was statistically significantly greater in patients
receiving HFA-BDP than HFA-FP at week 3. Mean daily
b-agonist use and percentage of days of use of b-agonist
was also reduced in both groups; the difference was not
statistically significant between the groups.
There is some evidence that measurement of markers,
such as eosinophil count and plasma ECP levels, can give
an indication of the anti-inflammatory effects of inhaled
corticosteroids (16,17). In this study, eosinophil count was
reduced by a statistically significantly greater amount in the
HFA-BDP group at weeks 3 and 8, and for ECP value at
week 8. The results should be seen in the context that the
baseline eosinophil count in the HFA-BDP group was
significantly higher than in the HFA-FP group.
Looking at safety of the two study treatments, both
HFA-BDP extra-fine aerosol and HFA-FP were well
tolerated, with no differences detected in the incidence or
severity of adverse events between the groups. With regard
to systemic activity, it has previously been shown that FP
can cause suppression of adrenocortical activity even at
clinically recommended doses (18) and the results of a
recently published 3-week, cross-over study in 16 healthy
volunteers show that HFA-FP caused significant dose-
related adrenal suppression (P50?01) (19). However, in
this study, no significant effects were seen for HFA-BDP or
HFA-FP on adrenal suppression, as assessed by UCC
ratios, and no significant differences were detected between
the effects of the two agents on this parameter. The mean
change from baseline in the HFA-BDP group was close to
zero.
What underlies the observed differences between the
dosing ratios for CFC and HFA inhaled corticosteroid
formulations? A number of factors may be implicated. InHFA-BDP, BDP is present in a solution of HFA
propellant, whereas in CFC-BDP, the BDP is in a
suspension of CFC propellant. BDP particles from HFA-
BDP extra-fine aerosol are, on average, three to four times
smaller than the BDP particles released from CFC-BDP
inhalers (1?1mm vs. 3?5–4?0mm), therefore, the ‘extra-fine
particle fraction’, that is, the fraction of the dose capable of
reaching the airways of the lung, is greater (4). Studies in
patients have shown a lung deposition of 50–60% with
HFA-BDP (4,20).
Particle size is not, of course, the only characteristic of
the inhaled corticosteroid that may affect the amount of
drug reaching the inflamed airways and hence the ecacy
of these agents. Spray force also influences lung deposition.
A more gentle, more diffuse inhaler spray force reduces
oropharyngeal deposition (21), and according to particle
dynamics, permits a greater percentage of inhaled drug to
reach the lower airways of the lung (22). This is the case
with HFA-BDP extra-fine aerosol (21).
Lung deposition studies comparing CFC-BDP, HFA-
BDP extra-fine aerosol, CFC-FP, and HFA-FP would be of
interest to determine whether differences in ecacy and
dosing regimens are a consequence of differences in lung
deposition attributable to inhaler characteristics. Results
from a mechanical lung model with CFC-FP, HFA-BDP
extrafine aerosol, and CFC-BDP indicate that the deposi-
tion pattern with CFC-FP is similar to that seen with CFC-
BDP (7). However, two-dimensional radiolabelled gamma
scintigraphy lung deposition studies have not yet been
published with CFC-FP or HFA-FP in patients. Compara-
tive in-vivo studies with HFA-BDP extra-fine aerosol and
CFC-BDP have shown at least a 10-fold increase in lung
deposition with HFA-BDP extra-fine aerosol compared
with CFC-BDP with an increase in the proportion of the
drug deposited in the peripheral airways (5).
An in-vitro study using an Andersen cascade impactor
found that HFA-FP 125 mg and CFC-FP 125 mg had similar
performance in terms of particle size distribution (23).
Furthermore, a comparative pharmacokinetic and pharma-
codynamic study performed with CFC-FP and HFA-FP
indicated similar systemic bioavailability for the two agents
(26?4% vs. 26?6%) (24) and HFA-FP and CFC-FP have
been shown to have equivalent anti-asthmatic ecacy on
peak flow in a cross-over study in 112 patients with severe
asthma (3). The results of dose-response studies and in-vivo
lung deposition studies with CFC-FP and HFA-FP are
awaited with interest.
With the phasing out of pMDIs containing CFC
propellants and the advent of new CFC-free inhaled
corticosteroid formulations, physicians are faced with new
therapeutic options, and revised dosing strategies. When
making the choice between therapies, there are several
factors to consider in addition to ecacy and daily steroid
load. These include cost, patient preference and long-term
safety. The inhaled corticosteroids are well-established as
the most cost-effective form of treatment for preventing
asthma (25). HFA-BDP extra-fine aerosol, also available as
a breath-actuated AutohalerTM inhalation device, is nota-
bly one of the least costly formulations available according
to calculations from the British National Formulary
HFA-BDP AND HFA-FP IN ASTHMA 219(March, 1998) (25). The importance of a patients’s
preference for a certain device/formulation should not be
underestimated. New products must be equally, or more,
acceptable to the patients as their previous inhaler. Lack of
confidence in a new inhaler can lead to reduced compliance
— a major problem in chronic disorders such as asthma
where patients must take medication regularly regardless of
their symptom status (26). In a study of patient preferences
in 385 patients, 96% found it easy to switch from a CFC-
BDP inhaler to the HFA-BDP extra-fine aerosol (27).
Furthermore, 60% of patients indicated that they preferred
the HFA-BDP extra-fine aerosol. It remains for future
studies to assess whether the patient preferences found in
this study also apply to other HFA inhalers, such as HFA-
FP.
Finally, looking at long-term effects of asthma medica-
tions, the main concern with inhaled corticosteroid treat-
ments is the potential for dose-related systemic effects.
Increasing evidence suggests that highly lipophilic drugs
like FP may have a less favourable systemic safety; a meta-
analysis of 27 studies showed that FP exhibits greater dose-
related systemic bioactivity compared with other inhaled
corticosteroids (28). The long half-life of FP (8–14 h) may
increase the risk of accumulation with repeated dosing (9).
Long-term safety studies with HFA-FP are required. A 12-
month study comparing HFA-BDP extra-fine aerosol and
CFC-BDP found no statistically significant differences
between the agents with regard to systemic safety (29).
In conclusion, this study demonstrated that HFA-BDP
at a dose of 800mg day71 provided at least the same ecacy
and safety as HFA-FP at a dose of 1000 mg day71 in a
population of patients with moderate-to-severe sympto-
matic asthma. Further studies comparing dose-response for
ecacy and long-term systemic safety of the two agents, in
addition to lung deposition studies with HFA-FP, will help
physicians in their rationale for switching patients from
CFC-based inhalers to the new HFA alternatives.
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